Format

Send to

Choose Destination
Drug Healthc Patient Saf. 2018 Apr 18;10:27-36. doi: 10.2147/DHPS.S133286. eCollection 2018.

Evaluating cardiac risk: exposure response analysis in early clinical drug development.

Author information

1
Data Management and Biometric, Celerion, Montreal, QC, Canada.
2
Scientific Affairs, Celerion, Lincoln, NE, USA.
3
Global Clinical Research, Celerion, Tempe, AZ, USA.

Abstract

The assessment of a drug's cardiac liability has undergone considerable metamorphosis by regulators since International Council for Harmonization of Technical Requirement for Pharmaceuticals for Human Use E14 guideline was introduced in 2005. Drug developers now have a choice in how proarrhythmia risk can be evaluated; the options include a dedicated thorough QT (TQT) study or exposure response (ER) modeling of intensive electrocardiogram (ECG) captured in early clinical development. The alternative approach of ER modeling was incorporated into a guidance document in 2015 as a primary analysis tool which could be utilized in early phase dose escalation studies as an option to perform a dedicated TQT trial. This review will describe the current state of ER modeling of intensive ECG data collected during early clinical drug development; the requirements with regard to the use of a positive control; and address the challenges and opportunities of this alternative approach to assessing QT liability.

KEYWORDS:

QT/QTc; assay sensitivity; concentration-effect modeling; intensive ECG collection; intersection union test; moxifloxacin; positive control; thorough QT study

Conflict of interest statement

Disclosure JG, SP, BHM, and RML are employees of Celerion. The authors report no other conflicts of interest in this work.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center